Delving into the Latest Updates on PG-018 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

JAK1

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)

Therapeutic Areas

Immune System DiseasesUrogenital Diseases

Active Indication

Glomerulonephritis, Membranous

Inactive Indication-

Originator Organization

Beijing Puqi Pharmaceutical Technology Co Ltd.Startup

Active Organization

Beijing Puqi Pharmaceutical Technology Co Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Three Gram-positive, anaerobic, pleomorphic strains (PG10(T), PG18 and PG22), were selected among five strains isolated from pig slurries while searching for host specific bifidobacteria to track the source of fecal pollution in water. Analysis of the 16S rRNA gene sequence showed a maximum identity of 94% to various species of the family Bifidobacteriaceae. However, phylogenetic analyses of 16S rRNA and HSP60 gene sequences revealed a closer relationship of these strains to members of the recently described Aeriscardovia, Parascardovia and Scardovia genera, than to other Bifidobacterium species. The names Neoscardovia gen. nov. and Neoscardovia arbecensis sp. nov. are proposed for a new genus and for the first species belonging to this genus, respectively, and for which PG10(T) (CECT 8111(T), DSM 25737(T)) was designated as the type strain. This new species should be placed in the Bifidobacteriaceae family within the class Actinobacteria, with Aeriscardovia aeriphila being the closest relative. The prevailing cellular fatty acids were C(16:0) and C(18:1)ω9c, and the major polar lipids consisted of a variety of glycolipids, diphosphatidyl glycerol, two unidentified phospholipids, and phosphatidyl glycerol. The peptidoglycan structure was A1γmeso-Dpm-direct. The GenBank accession numbers for the 16S rRNA gene and HSP60 gene sequences of strains PG10(T), PG18 and PG22 are JF519691, JF519693, JQ767128 and JQ767130, JQ767131, JQ767133, respectively.

01 Feb 1983·Microbiology and ImmunologyQ4 · MEDICINE

Typing of Isolates of Mycoplasma pneumoniae and Mycoplasma salivarium by Growth Inhibitors Derived from Mycoplasmal Cells Treated with Chloroform

Q4 · MEDICINE

Article

Author: Itoh, Tohru ; Nakamura, Masahiro

AbstractIsolates of Mycoplasma pneumoniae and M. salivarium could be subclassified at the strain level by inhibitors (ch‐Mcin) derived from mycoplasmal cells treated with chloroform. Sixty‐one isolates of M. pneumoniae obtained from oral cavities of patients were divided into three types by their ch‐Mcin: a definite type which completely inhibits the growth of M. fermentans PG18, an indefinite type and a no‐inhibition type. Sixty‐seven isolates of M. salivarium were also divided into similar types by their ch‐Mcin which does or does not inhibit the growth of M. salivarium Hup127. In the case of isolates of M. pneumoniae and M. salivarium belonging to the indefinite type which gave ambiguous patterns in the ch‐Mcin typing, it was demonstrated that they could be clearly typed by further testing after repeated cloning.

Mikrobiolohichnyi zhurnal (Kiev, Ukraine : 1993)

[The validation of the possible use of monosugars and 6-azacytidine for the elimination of Mollicutes associated with HIV/AIDS from the human urogenital tract].

Article

Author: Skrypal', I H ; Malynovs'ka, L P ; Shalamaĭ, A S ; Tokovenko, I P ; Havrylko, L O ; Aleksieieva, I V ; Onyshchenko, A M ; Panchenko, L P

A search for the methods new in principle which should block and eliminate AIDS-associated mycoplasmas was carried out. This work was conducted in two ways: 1) inhibition of vital activity of Mycoplasma fermentans PG-18 and Acholeplasma laidlawii PG-8 by 6-azacytidine; 2) establishment of carbohydrate composition of receptors for these mycoplasmas aimed at the competitive elimination of these microorganisms from urogenital tract of a man using carbohydrates. It is established that a 50%-inhibiting concentration of 6-azacytidine was 23.4 micrograms/ml for M. fermentans PG-18 and 62.5 micrograms/ml for A. laidlawii PG-8. alpha-D-glucose and N-acetylneuramine acid are two terminal carbohydrates that can serve as receptors for M. fermentans on human mucous membranes while D-mannose and N-acetyl-D-glucosamine for A. laidlawii PG-8. alpha-D-glucose in concentration 75 mM and N-acetylneuramine acid in concentration 150 mM competitively inhibit reception of M. fermentans on mucosae, while D-mannose in concentration 150 mM and N-acetyl-D-glucosamine in concentration 75 mM are antireceptor substances for A. laidlawii.

100 Deals associated with PG-018

Login to view more data